is well-established and further substantiated by beneficial therapeutic effects of rituximab (anti-CD20 B cell targeted therapy). However, this results in prolonged B cell depletion while long-lived plasma cells are not targeted. Thus there is a need for novel therapeutics targeting cells in the B-cell lineage in AAV. Novel targets might be encountered in the NF-kB signalling pathway, which acts downstream of various B cell surface receptors, including the B cell antigen receptor, CD40, BAFFR and TLRs, and is crucially involved in B cell responses. Objectives To identify whether inhibition of NF-kB signalling by novel pharmacological inhibitors is effective in targeting B cell responses in general and more specifically blocks (auto) antibody production and plasmablast differentiation in B cells from AAV patients. Methods PBMC and sorted B cells from AAV patients and healthy donors were cultured with T cell-dependent (antiIgM +anti CD40+IL-21) and T cell-independent (CpG +IL-2) stimuli. NF-kB signalling was targeted in these cultures by small molecule inhibitors of NF-kB inducing kinase (NIK, non-canonical NF-kB signalling) and IKKb (canonical NF-kB signalling). Downstream NF-kB signalling and nuclear NF-kB translocation was determined by Western blot and confocal imaging. Effects on B cell proliferation and differentiation were determined by CFSE dilution assays and flow cytometric analysis of B cell markers. (Auto)antibody production was measured by ELISA. Results In B cells, targeting of NIK and IKKb effectively inhibited non-canonical or canonical NF-kB signalling, respectively. In a B cell stimulation assay, NIK and IKKb inhibition significantly reduced T cell-dependent (anti-IgM +anti CD40+IL-21) and T cell-independent (CpG +IL-2) B cell proliferation, plasmablast differentiation (CD27++/CD38+), and antibody production. The effects of NIK inhibition appeared to be B cellspecific as T cell proliferation was largely unaffected. Introduction Rheumatoid arthritis (RA) is a chronic, inflammatory arthritis that evolves along an immunological and inflammatory disease continuum. The era of targeted biological therapies has been transformative; however, a significant unmet need is the effective tailoring of therapy to deliver optimal treatment responses. In addition, the concept of a window of opportunity is well-recognised whereby early commencement of treatment confers improved outcomes compared to delayed treatment. The importance of pro-inflammatory cytokines TNF and IL-6 in particular, is well recognised; but high, homogeneous response in early RA (ERA) compared to later RA remains unexplained. Objectives The present project focuses on measuring the phosphorylation of STAT3 (p-STAT3) levels as an indication of the activation of IL-6/JAK-STAT signalling pathway at different disease stages (early and established/later). The main aim is to evaluate the variation in cell-subset IL-6 signalling and its association with response to treatment which included IL-6 targeted therapy (Tocilizumab-TCZ) as well as other bDMARD. Methods Phosphorylation of IL-6/JAK-STAT key transcription factor STAT3 (p-STAT3) was measured using multiparameter phosphoflow cytometry (phosflow) in T-, B-cells and monocytes isolated from peripheral blood of RA patients. Patients cohorts represented groups at different stages of RA: Treatment-naïve Early RA (ERA group) n=20. Later RA group 
